• Subjects with histopathological confirmation of newly diagnosed (Cohort A) or locally recurrent (Cohort B) malignant cutaneous lesions of the following histopathologies:

‣ SCC

⁃ BCC

⁃ Lentigo maligna melanoma (Dubreuilh melanoma)

⁃ Carcinosarcoma

• Acceptable tumor locations include the following:

‣ Skin (facial, scalp, extremities, torso)

⁃ Lips

⁃ Eyelids

• Subjects with a tumor size ≤ 7 centimeters in the longest diameter.

• Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds.

• Measurable disease according to RECIST v1.1.

• Subjects over 18 years old.

• Subjects' ECOG Performance Status Scale is \< 2.

• Subjects' life expectancy is more than 6 months.

• Platelet count ≥100,000/mm3.

• International normalized ratio of prothrombin time ≤1.8.

• Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.

• Subjects are willing to sign an informed consent form